J Eur Acad Dermatol Venearol
In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists have gone from obscure type 2 diabetes drugs to headline news for weight loss, polycystic ovary syndrome, and more
Pharmacokinetic modeling confirms this rapid onset with dose-dependent GH release (Agerso et al., 1999)
Control of dumping symptoms by somatostatin analogue in patients after gastric surgery
Commonly reported effects include nausea, constipation, diarrhea, and a reduced appetite
Of particular note was the lack of persistent receptor interactions for His1 of exendin-4, in contrast to the extensive interactions observed for GLP-1 (His7) and oxyntomodulin (His1), as described above (Fig